NEWS NEWS IN BRIEF


SMC CHALLENGED OVER ZYTIGA


The pharmaceutical company Janssen is to challenge the Scottish Medicines Consortium’s decision not to recommend Zytiga before chemotherapy for men with advanced prostate cancer in Scotland through an independent review.


The SMC recently published guidance outlining its decision not to recommend Zytiga, also known as abiraterone acetate, even though abiraterone has been approved for use after chemotherapy at a reduced cost, a discount which was offered to the SMC for use before chemotherapy.


“From the volume of Individual Patient Treatment Requests that are made, we know that there is considerable demand for abiraterone from patients and clinicians in Scotland,” said Mark Hicken, Managing Director of Janssen UK & Ireland.


“Given that the evidence we submitted fully meets the Scottish Medicines Consortium criteria for end of life medicines we hope they will now expedite this review and agree a way to make this important medicine routinely available before chemotherapy for all eligible men with metastatic prostate cancer in Scotland.”


DATE FOR YOUR DIARY


RPS Scotland has always seen public engagement as their priority. They want to hear patients’ views on pharmacy and develop a better understanding of how we can improve the pharmacist’s role in delivering high-quality and person- centred care. With this in mind, we are hosting a Public & Patient Involvement Seminar on June 3rd, 10.30am until 2.30pm at our Edinburgh Offi ce on 106 Holyrood Road.


RPS Scotland hopes to welcome representatives from a range of health charities and patient groups. We plan to address topics such as the experiences of patients and the public, the need for change, how pharmacists fi t into the healthcare system and the new Scottish Government proposals for the profession.


As always, they are keen to promote understanding of how pharmacists can contribute to improving both individual and public health. RPS Scotland see this engagement seminar as crucial in enabling them to do this effectively.


If you are interested in becoming involved in this seminar, then please email Practice and Policy Lead, Aileen Bryson at aileen.bryson@rpharms.com


8 - SCOTTISH PHARMACIST


Clinical trial design braced for challenge


A huge number of clinical trials are poorly designed and as such the results they produce can be irrelevant to real end users.


Now researchers at the University of Aberdeen through collaboration with over 80 international researchers, clinicians and policymakers and leaders in this fi eld have developed a tool which helps trial designers to create more useful trials.


The PRECIS-2 tool is an improved version of a tool devised by members of the same team and already being used by trial designers in the UK and is already being tested by the National Institute of Health in the US.


“Around 25,000 randomised trials are published every year around the world,” explains Professor Shaun Treweek from the University of Aberdeen’s Health Services Research Unit. “They are seen as the ‘gold standard’ test for proving a new drug or treatment is better than the existing one.


“The problem is that these trials are often fundamentally fl awed from the outset because the parameters of the test are often too narrow. In order to make a ‘cleaner’ experiment, trial designers may exclude people with underlying health problems, or the elderly, or carry out all the tests in hospitals, rather than GP practices even though the treatment would be used mainly by GPs, for example.


“If the trial doesn’t include the same kind of people who will be receiving the treatment, or those who will be administrating it, then the results are likely to be largely irrelevant in


practice. For example, a team in New Zealand looked at 17 major asthma trials in an international treatment guideline and found that of the people in their community receiving treatment for asthma – only around six per cent were eligible for any one of these trials.”


Professor Treweek says the shortcomings of many randomised trials have been recognised by the medical community for 50 years, but the same mistakes are repeated to this day because many of those around the world who design trials have not been properly trained in research methods.


Now, Professor Treweek and Kirsty Loudon at the University of Aberdeen and colleagues in Dundee and Canada have devised a new easy-to-use tool,


which helps trial designers at every stage of the design process to ensure they are making design choices that match the information needs of the people they are designing the trial for, which generally means patients and health professionals.


“The PRECIS-2 tool helps trial teams work through key questions in a very explicit way,” says Professor Treweek. “At the end – the data you input produces an image. If your decisions are consistent, it looks like a ‘wheel’. If it’s a ‘bumpy’ wheel it means your decisions have been inconsistent. If it’s a wide wheel then it means you’ve designed a trial that is likely to be highly relevant to real world practice. A narrow wheel means they’ve designed a tightly controlled experiment which may be useful in the future but is unlikely to resonate with people in the real world. It’s a great way of identifying potential fl aws in the design of a trial before any real money, time and effort has been spent on the trial itself.


“The end goal is to see the use of this tool taught as standard ‘good practice’ for trial designers so it becomes a routine part of the process. Funders are starting to take notice of this and we hope many will consider using it to ensure that their money is being spent on trials that have relevant results and real impact.”


Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14  |  Page 15  |  Page 16  |  Page 17  |  Page 18  |  Page 19  |  Page 20  |  Page 21  |  Page 22  |  Page 23  |  Page 24  |  Page 25  |  Page 26  |  Page 27  |  Page 28  |  Page 29  |  Page 30  |  Page 31  |  Page 32  |  Page 33  |  Page 34  |  Page 35  |  Page 36  |  Page 37  |  Page 38  |  Page 39  |  Page 40  |  Page 41  |  Page 42  |  Page 43  |  Page 44  |  Page 45  |  Page 46  |  Page 47  |  Page 48  |  Page 49  |  Page 50  |  Page 51  |  Page 52  |  Page 53  |  Page 54  |  Page 55  |  Page 56